Cohance Lifesciences Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Press Release".

Cohance Lifesciences is investing USD 10 million to build a new cGMP bioconjugation suite at its U.S. subsidiary NJ Bio's Princeton, New Jersey facility, aimed at strengthening its end-to-end Antibody-Drug Conjugate (ADC) capabilities. The new suite will integrate payload-linker synthesis and bioconjugation under one roof, with the capacity to manufacture up to 2 kg of ADCs for clinical supply, and is expected to be operational by the end of Q4 FY26. NJ Bio is already executing a major ADC program for an existing customer and is in advanced discussions with 3-4 additional customers whose programs are expected to align with the facility's commissioning. The move positions Cohance to capture demand in the fast-growing global ADC market, driven by rising cancer incidence and targeted immuno-oncology therapies. For context, the company posted FY25 revenue of around INR 26 billion (~USD 313 million) with 33.6% adjusted EBITDA margins.